sGC Stimulator Praliciguat Suppresses Stellate Cell Fibrotic Transformation and Inhibits Fibrosis and Inflammation in Models of NASH

Proceedings of the National Academy of Sciences of the United States of America (PNAS) (2019)

Katherine C. Hall, Sylvie G. Bernier, Sarah Jacobson, Guang Liu, Ping Y. Zhang, Renee Sarno, Victoria Catanzano, Mark G. Currie, and Jaime L. Masferrer

This journal article characterizes the effects of Cyclerion’s systemic sGC stimulator, praliciguat, in models of nonalcoholic steatohepatitis (NASH), identifying key target cells and downstream signaling pathways responsible for the observed pharmacology. These data support the potential utility of sGC stimulation as a promising mechanism in the treatment of NASH and fibrotic liver diseases.

Return to Archive